Flupirtine: Pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 9, 2009, Pages 1495-1500

  Klawe, C ^a   Maschke, M ^a  

^a Bruederkrankenhaus Trier ^*  (Germany)

Author keywords

Alzheimer's disease; Creutzfeld Jakob disease; Flupirtine; G protein activated inwardly rectifying K+ channels (GIRKs); Kv7 channels; Multiple sclerosis; Muscle; Pain; Potassium channels; Selective neuronal potassium channel openers (SNEPCO); Spasticity

Indexed keywords

ANALGESIC AGENT; DIHYDROCODEINE; FLUPIRTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PARACETAMOL;

ALLERGIC REACTION; ALZHEIMER DISEASE; ANOREXIA; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DIZZINESS; DRUG ACTIVITY; DRUG INFORMATION; DRUG RESEARCH; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MULTIPLE SCLEROSIS; NAUSEA; NEUROPROTECTION; NONHUMAN; PAIN; RESTLESSNESS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; URINE COLOR; URTICARIA; XEROSTOMIA;

ALZHEIMER DISEASE; AMINOPYRIDINES; ANALGESICS; ANIMALS; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 67650660898     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902988528     Document Type: Review

References (44)

1. Nickel B, Herz A, Jakovlev V, Tibes U. Mechanism of action of the analgesic flupirtine. Arzneimittelforschung 1985;35(9):1402-1409
2. Nickel B. The antinociceptive activity of flupirtine: a structurally new analgesic. Postgrad Med J 1987;63(Suppl 3):19-28 (Pubitemid 17146934)
3. Nickel B, Jakovlev V, Szelenyi I. The effect of flupirtine, various analgesics and muscle relaxants on skeletal muscle tone in the conscious rat. Arzneimittelforschung 1990;40(8):909-911 [in German] (Pubitemid 20241089)
4. Szelenyi I, Nickel B. Pharmacological profile of flupirtine, a novel centrally acting, non-opioid analgesic drug. Agents Actions Suppl 1991;32:119-123
5. Darius H, Schrör K. The action of flupirtine on prostaglandin formation and platelet aggregation invitro. Arzneimittelforschung 1985;35(1):55-59 (Pubitemid 15195781)
6. Block F, Pergande G, Schwarz M. Flupirtine protects against ischaemic retinal dysfunction in rats. Neuroreport 1994;5(18):2630-2632
7. Rupalla K, Cao W, Krieglstein J. Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca2+ concentration. Eur J Pharmacol 1995;294(2-3):469-473 (Pubitemid 26013239)
8. Perovic S, Schleger C, Pergande G, et al. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur J Pharmacol 1994;288(1):27-33
9. Osborne NN, Cazevieille C, Wood JP, et al. Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist. Gen Pharmacol 1998;30(3):255-263 (Pubitemid 28046493)
10. Schwarz M, Schmitt T, Pergande G, Block F. N-methyl-D-aspartate and alpha 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats. Eur J Pharmacol 1995;276(3):247-255
11. Kornhuber J, Bleich S, Wiltfang J, et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication. J Neural Transm 1999;106(9-10):857-867 (Pubitemid 29516055)
12. Jakob R, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurones. Br J Pharmacol 1997;122(7):1333-1338 (Pubitemid 27503922)
13. Stanfield PR, Nakajima Y, Yamaguchi K. Substance P raises neuronal membrane excitability by reducing inward rectification. Nature 1985;315(6019):498-501 (Pubitemid 15232866)
14. Sheridan PH, Seaman CA, Narang PK, et al. Pilot study of flupirtine in refractory seizures. Neurology 1986;36(Suppl 1)
15. Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 2003;7(6):737-748 (Pubitemid 37541260)
16. Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol 2009 [Epub ahead of print]
17. Martire M, Castaldo P, D'Amico M, et al. Mchannels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J Neurosci 2004;24(3):592-597 (Pubitemid 38166483)
18. Mackie AR, Brueggemann LI, Henderson KK, etal. Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressured arteries, and invivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 2008;325(2):475-483 (Pubitemid 351574788)
19. Wladyka CL, Kunze DL. KCNQ/M currents contribute to the resting membrane potential in rat visceral sensory neurons. J Physiol 2006;575(Pt1):175-189 (Pubitemid 44178136)
20. Yeung SY, Pucovsky V, Moffatt JD, et al. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 2007;151(6):758-770
21. Blackburn-Munro G, Dalby-Brown W, Mirza NR, etal. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005 Spring;11(1):1-20
22. Obermeier K, Niebch G, Thiemer K. Pharmacokinetics and biotransformation of the analgesic flupirtine in the rat and dog. Arzneimittelforschung 1985;35(1):60-67 (Pubitemid 15195782)
23. Hlavica P, Niebch G. Pharmacokinetics and biotransformation of the analgesic flupirtine in humans. Arzneimittelforschung 1985;35(1):67-74 (Pubitemid 15153731)
24. Methling K, Reszka P, Lalk M, et al. Investigation of the invitro metabolism of the analgesic flupirtine. Drug Metab Dispos 2009;37(3):479-493 [Epub 2008 Dec 12]
25. Abrams SM, Baker LR, Crome P, et al. Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment. Postgrad Med J 1988;64(751):361-363 (Pubitemid 18130640)
26. Moore RA, Bullingham RE, Simpson S, et al. Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br J Anaesth 1983;55(5):429-432
27. Galasko CS, Courtenay PM, Jane M, Stamp TC. Trial of oral flupirtine maleate in the treatment of pain after orthopaedic surgery. Curr Med Res Opin 1985;9(9):594-601 (Pubitemid 16241023)
28. Mastronardi P, D'Onofrio M, Scanni E, et al. Analgesic activity of flupirtine maleate: a controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988 Sep-Oct;16(5):338-48. J Int Med Res 1988;16(5):338-348
29. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987;63(Suppl 3):67-70 (Pubitemid 17146942)
30. Heusinger JH. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgrad Med J 1987;63(Suppl 3):71-79 (Pubitemid 17146943)
31. Lüben V, Müller H, Lobisch M, Wörz R. Treatment of tumor pain with flupirtine. Results of a double-blind study versus tramadol. Fortschr Med 1994;112(19):282-286
32. Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984;9(3):204-212 (Pubitemid 14026815)
33. Wörz R. Flupirtine in chronic myofacial pain conditions. Fortschr Med 1991;109(6):158-160
34. Ringe JD, Miethe D, Pittrow D, Wegscheider K. Analgesic efficacy of flupirtine in primary care of patients with osteoporosis related pain. A multivariate analysis. Arzneimittelforschung 2003;53(7):496-502
35. Müller-Schwefe GH, Uberall MA. Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. Results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension. MMW Fortschr Med 2008;149(Suppl 4):153-161
36. Li C, Ni J, Wang Z, et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008;24(12):3523-3530
37. Göbel H, Schmid J, Heinze A, Pergande G. Reduction of spastic increased muscle tone in multiple sclerosis by the nonopioid analgesic flupirtine. Schmerz 1999;13(5):324-331 (Pubitemid 29500856)
38. Schwarz M, Nolden-Koch M, Purr J, et al. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. J Neural Transm 1996;103(5):581-590 (Pubitemid 26383644)
39. Schmidt WJ, Schuster G, Wacker E, Pergande G. Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 1997;327(1):1-9 (Pubitemid 27220214)
40. Putzki N, Maschke M, Drepper J, et al. Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson's disease. J Neurol 2002;249(7):824-828 (Pubitemid 34754217)
41. Sättler MB, Williams SK, Neusch C, et al. Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am J Pathol 2008;173(5):1496-1507
42. Boscia F, Annunziato L, Taglialatela M. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology 2006;51(2):283-294 (Pubitemid 44061890)
43. Dhar S, Bitting RL, Rylova SN, et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol 2002;51(4):448-466 (Pubitemid 34260775)
44. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62(5):714-718 (Pubitemid 38298945)